Tenaya Therapeutics (TNYA) Competitors $0.44 0.00 (-0.93%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. CYBN, SLS, NKTX, EPRX, NLTX, ACRS, TNGX, LRMR, ADCT, and GLSIShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Cybin (CYBN), SELLAS Life Sciences Group (SLS), Nkarta (NKTX), Eupraxia Pharmaceuticals (EPRX), Neoleukin Therapeutics (NLTX), Aclaris Therapeutics (ACRS), Tango Therapeutics (TNGX), Larimar Therapeutics (LRMR), ADC Therapeutics (ADCT), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Cybin SELLAS Life Sciences Group Nkarta Eupraxia Pharmaceuticals Neoleukin Therapeutics Aclaris Therapeutics Tango Therapeutics Larimar Therapeutics ADC Therapeutics Greenwich LifeSciences Cybin (NYSE:CYBN) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability. Is CYBN or TNYA more profitable? Cybin's return on equity of -37.58% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Tenaya Therapeutics N/A -86.17%-71.14% Does the MarketBeat Community favor CYBN or TNYA? Tenaya Therapeutics received 27 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 84.62% of users gave Tenaya Therapeutics an outperform vote. CompanyUnderperformOutperformCybinOutperform Votes17100.00% Underperform VotesNo VotesTenaya TherapeuticsOutperform Votes4484.62% Underperform Votes815.38% Which has more risk and volatility, CYBN or TNYA? Cybin has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.99, meaning that its share price is 199% more volatile than the S&P 500. Which has stronger valuation and earnings, CYBN or TNYA? Cybin is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.38-1.60Tenaya TherapeuticsN/AN/A-$124.08M-$1.16-0.38 Does the media prefer CYBN or TNYA? In the previous week, Tenaya Therapeutics had 2 more articles in the media than Cybin. MarketBeat recorded 7 mentions for Tenaya Therapeutics and 5 mentions for Cybin. Cybin's average media sentiment score of 1.30 beat Tenaya Therapeutics' score of -0.17 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of CYBN or TNYA? 17.9% of Cybin shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer CYBN or TNYA? Cybin presently has a consensus target price of $86.00, indicating a potential upside of 1,125.07%. Tenaya Therapeutics has a consensus target price of $6.25, indicating a potential upside of 1,313.71%. Given Tenaya Therapeutics' higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Cybin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTenaya Therapeutics beats Cybin on 9 of the 16 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.92M$2.93B$5.38B$8.39BDividend YieldN/A1.71%5.21%4.10%P/E Ratio-0.3130.5026.7619.71Price / SalesN/A400.15389.94117.54Price / CashN/A168.6838.2534.62Price / Book0.223.286.804.50Net Income-$124.08M-$72.17M$3.23B$248.18M7 Day Performance1.10%2.96%1.52%0.23%1 Month Performance-2.79%3.25%10.04%12.39%1 Year Performance-90.00%-28.29%16.73%7.07% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.442 of 5 stars$0.44-0.9%$6.25+1,326.9%-89.4%$71.25MN/A-0.30110CYBNCybin2.718 of 5 stars$6.71-4.8%$86.00+1,181.5%N/A$144.33MN/A-1.5350News CoverageSLSSELLAS Life Sciences Group0.3176 of 5 stars$1.52-2.9%N/A+19.7%$143.24M$1M-2.2010NKTXNkarta1.9843 of 5 stars$2.02+4.4%$14.83+636.1%-74.0%$142.27MN/A-1.07140Positive NewsAnalyst RevisionGap UpEPRXEupraxia Pharmaceuticals2.2038 of 5 stars$3.90+2.5%$10.50+169.5%+32.3%$139.67MN/A-5.4129Gap UpNLTXNeoleukin TherapeuticsN/A$14.73-1.8%N/A-45.5%$138.43MN/A-4.7490Gap UpHigh Trading VolumeACRSAclaris Therapeutics2.8743 of 5 stars$1.28+1.2%$10.67+736.6%+9.3%$138.06M$18.72M-2.45100Positive NewsGap DownTNGXTango Therapeutics1.8613 of 5 stars$1.28+12.3%$12.33+863.5%-74.7%$137.95M$42.07M-1.0890LRMRLarimar Therapeutics2.0736 of 5 stars$2.09-1.7%$19.63+841.2%-75.5%$133.50MN/A-1.8130Positive NewsGap UpADCTADC Therapeutics2.6735 of 5 stars$1.32+3.5%$7.75+489.4%-47.6%$130.42M$70.84M-0.55310Analyst RevisionGLSIGreenwich LifeSciences1.2042 of 5 stars$9.58+1.5%$39.00+307.3%-28.1%$127.10MN/A-11.973Positive NewsEarnings Report Related Companies and Tools Related Companies Cybin Competitors SELLAS Life Sciences Group Competitors Nkarta Competitors Eupraxia Pharmaceuticals Competitors Neoleukin Therapeutics Competitors Aclaris Therapeutics Competitors Tango Therapeutics Competitors Larimar Therapeutics Competitors ADC Therapeutics Competitors Greenwich LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TNYA Stock Free TNYA Stock Alerts